by CN Bio. | Apr 26, 2022 | NASH, Press releases
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery Cambridge, UK, 26 April 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that...
by CN Bio. | Dec 1, 2021 | Press releases
Next generation Organ-on-a-Chip technology listed second in Top 10 Innovations for 2021 System enables pre-clinical studies that simulate complex interaction and communication between organs, such as liver, gut, lung, and kidney, for accelerated drug discovery and...
by CN Bio. | Nov 9, 2021 | Press releases
Partnership focused on validation of novel Organ-on-a-Chip infection models Human-relevant single and multi-organ SARS-CoV-2 infected models developed using Innovate UK grant 3D lung cell culture technology to support more efficient and accurate COVID-19 therapeutic...
by CN Bio. | Oct 5, 2021 | Press releases
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system Represents first implementation of intellectual property licensed from Vanderbilt University to provide human-relevant...
by CN Bio. | Jul 27, 2021 | Press releases
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect on human health Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ...
by CN Bio. | Jul 19, 2021 | Press releases
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM...
